Head to Head Review: Aptose Biosciences (NASDAQ:APTO) & Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILDGet Free Report) and Aptose Biosciences (NASDAQ:APTOGet Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.

Analyst Recommendations

This is a summary of current ratings and price targets for Gilead Sciences and Aptose Biosciences, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gilead Sciences 0 10 9 1 2.55
Aptose Biosciences 0 0 4 0 3.00

Gilead Sciences currently has a consensus price target of $84.83, suggesting a potential downside of 0.14%. Aptose Biosciences has a consensus price target of $9.00, suggesting a potential upside of 2,359.02%. Given Aptose Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Aptose Biosciences is more favorable than Gilead Sciences.

Profitability

This table compares Gilead Sciences and Aptose Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Gilead Sciences 3.79% 29.34% 10.10%
Aptose Biosciences N/A -5,683.22% -279.77%

Insider & Institutional Ownership

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 26.6% of Aptose Biosciences shares are owned by institutional investors. 0.2% of Gilead Sciences shares are owned by company insiders. Comparatively, 4.6% of Aptose Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Gilead Sciences has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.

Earnings & Valuation

This table compares Gilead Sciences and Aptose Biosciences”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gilead Sciences $27.12 billion 3.90 $5.67 billion $0.82 103.60
Aptose Biosciences N/A N/A -$51.21 million ($6.20) -0.06

Gilead Sciences has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Aptose Biosciences on 10 of the 14 factors compared between the two stocks.

About Gilead Sciences

(Get Free Report)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

About Aptose Biosciences

(Get Free Report)

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.